Gilead appoints Dietmar Berger
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...
Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...
Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...
Sanofi's chief medical officer Dietmar Berger has previously said that lead-212 has a "differentiated biophysical and clinical profile, reinforcing its potential to be a transformative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback